Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
The laboratory is equipped to perform high-volume diagnostic testing services
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Revenue from operations up 26% to Rs. 768 crores
Extended Phenytoin Sodium Capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
The company increases its efficiency and is able to face the growing demand for its services.
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Subscribe To Our Newsletter & Stay Updated
